

Innate Pharma, Transgene, ImmunID, Inserm and the cancer hospital Centre Léon-Bérard announced the operational start of PLATINE, a joint immuno-monitoring platform

- *The five partners share the ambition to create a strong player in immuno-monitoring services for clinical and pre-clinical trials conducted with healthcare products*
- *Based at the new Center of Infectiology in Lyon since April 2009, Platine has started to perform immuno-monitoring tests for its founding partners*
- *Platine will soon offer its services to the biopharmaceutical industry as well as to academic institutions*

June 15, 2009 – Lyon, France: Innate Pharma (Euronext: IPH), Transgene (Euronext: TNG) – biotechnology companies specialized in the development of innovative immunotherapies, ImmunID – a biotechnology company specialized in diagnostic for personalized medicine, Inserm (French medical research agency) and the Centre Léon Bérard (a regional anti-cancer center) today announced the operational start of their shared immuno-monitoring platform of services, named Platine.

Platine today performs services for the development of the drug candidates of its founding members. The ambition of Platine is to develop an offer of immuno-monitoring¹ services for clinical and pre-clinical trials conducted with immuno-modulating products (vaccines, monoclonal antibodies, cytokines or all other molecule presenting an immuno-modulating activity) to the pharmaceutical and biopharmaceutical industries as well as to academic institutions.

Supported by a dedicated team composed of collaborators from its founding partners, Platine is based in the Center of Infectiology, a world center of excellence in infectiology, diagnostic and vaccines recently opened in Lyon. Platine has received the Lyonbiopôle label as well as grants, notably from the FUI (“Fonds Unique Interministériel”) and the FEDER (“Fonds Européen de Développement Régional”).

“Tools and methods required to extract relevant information from clinical trials, in order to guide choices for indications and administration schemes, are often very sophisticated. There is a very specific expertise that justifies the sharing of our forces in this field”, said Philippe Archinard, CEO of Transgene. He added: “Platine enables us to structure and create value with a specific expertise, which we have initially and separately developed for our own needs.”



¹ Immuno-monitoring consists in the monitoring (cellular, molecular, biochemical) and characterisation of an immune response after a given treatment. It is a very important step for the defining of the pharmacodynamic effect, the mechanistic properties, the therapeutic target or the safety profile of a drug candidate.

"We are very pleased to see a project shared by reference actors in the field of immunology reinforcing the expertise and the image of our cluster" said Yves Laurent, General Director of Lyonbiopôle. He added: "It is the core of our vocation to facilitate this type of collaborative projects between teams from industrial and academic actors, in a recognized scientific, medical and pharmaceutical environment".

For any additional information, please contact:

Samuel Salot

Bâtiment Domilyon - Centre d'infectiologie
321 avenue Jean Jaurès
69007 Lyon Gerland
Tel : +33 (0)4 37 70 87 00
Mail : samuel.salot@platine-lab.com



About Innate Pharma

Innate Pharma S.A. ("the company") is a clinical-stage biopharmaceutical company developing first-in-class immunotherapy drugs for cancer and other severe diseases. Founded in 1999, the company listed on NYSE-Euronext in Paris in 2006.

The company has significant expertise in identifying new targets and bringing novel drug candidates through to clinical proof-of-concept trials. It currently has seven proprietary drug candidates in development (two of which are in clinical trials with lead compound in Phase II clinical trial) and two programs out-licensed to Novo Nordisk A/S.

Based in Marseilles, France, Innate Pharma had 88 employees as at March 31, 2009.

Learn more about Innate-Pharma at www.innate-pharma.com

Press contacts:

Laure-Hélène Mercier
Director, Investor Relations
Tel. : +33 (0)4 30 30 30 87
lmmercier@innate-pharma.fr

Alize Public Relations : Caroline Carmagnol
Tel. : +33 (0)1 41 22 07 31
caroline@alizerp.com

About Transgene

Transgene, based in Illkirch, is a biopharmaceutical company dedicated to the development of immunotherapeutic products in oncology and infectious diseases. The company has three products in Phase II trials (TG4010, TG4001/R3484 and TG1042) and one compound in Phase I studies (TG4040). Transgene has concluded a strategic partnership agreement with Roche for the development of its TG4001/R3484 therapeutic vaccine to treat HPV-mediated diseases. Transgene has bio-manufacturing capacities for viral-based vectors and technologies available for out-licensing. Additional information about Transgene is available on the Internet at www.transgene.fr



- **Press contacts:**

Philippe Poncet
Chief Financial Officer
Tel. : 03 88 27 91 21

Elisabetta Castelli
Director Investor Relations
Tel. : 01 44 08 55 05

About ImmunID

ImmunID is leader in combinatorial immune repertoire analysis. Thanks to its original concept of "Immune Weather Forecast" ImmunID offers innovative immunomonitoring & diagnostic solutions to characterize immune dysfunction and analyse the impact of immunotherapy on Immune Repertoire.

In the context of personalized medicine, ImmunTraCkeR® and Immun'Ig® solutions are used as biomarkers, for the measure of efficacy of immunomodulators or of immunodeficiencies

Additional information about ImmunID is available at www.immunid.com

- **Press contact:**

Nicolas Pasqual
Tel : +33 (0)4 38 78 57 70

About Centre Léon Bérard

The Léon Bérard Centre is a cancer centre with three main duties that include patient care, training and research. With its research facilities being located within the hospital grounds, new scientific and technological advances are quickly made available to cancer patients. The Centre hosts several research units and teams dedicated to basic, applied or clinical cancer research and are affiliated with the Lyon1 University, the INSERM and the CNRS. The research facilities also include innovative and sophisticated platforms and a biological resource centre. About 280 people collaborate to develop various projects in molecular genetics, in biology (oncology and immunotherapy), radiotherapy, surgery or health economics. The general objectives are to identify and elucidate the mechanisms involved in the development of tumors, to characterize molecular markers of prognosis, and facilitate the development of innovative diagnostic tools and treatment strategies.

About INSERM

Created in 1964, Inserm is a public institution with a scientific and technical vocation, under the dual auspices of the Ministry of Health and the Ministry of Higher Education and Research. Inserm is the only French public research body entirely dedicated to human health. Its researchers are committed to studying all diseases, whether common or rare, through their research in the fields of biology, medicine and public health.

About Lyonbiopôle

Lyonbiopôle is a world competitive cluster focused on the fight against human and animal infectious diseases. It is founded upon the expertise of the Lyon/Grenoble area, which boasts a strong synergy between industrial biology, structural biology and micro & nanotechnology. Designed as a “factory” for producing multi-partner R&D projects, Lyonbiopôle helps to link the industrial and academic spheres and bring them closer together. It aims to become an innovation driver, making the region and its firms ever more competitive.

Lyonbiopôle’s Board of Directors includes representatives of: bioMérieux, BD France, Sanofi Pasteur, Merial, PX’Thérapeutics, Alizé Pharma, CEA, Inserm, Claude Bernard Lyon 1 University, and the Mérieux Foundation

Permanent members:

Greater Lyon, The Rhône-Alpes Region, DRIRE Rhône-Alpes and Grenoble Alpes Metro.



Disclaimer: This press release contains certain forward-looking statements, which are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in Transgene or Innate Pharma in any country.